Macular edema is a condition in which there is swelling in the macula, the part of the retina that gives you your best vision. This swelling can cause your vision to decline. When diagnosed early and treated, you vision usually can be preserved. However, if the swelling goes untreated for a long time, it can cause permanent vision loss. We think that the three eye drop regimens in this study, difluprednate, difluprednate plus nepafenac, and prednisolone acetate plus nepafenac, might be effective in treating uveitic macular edema. Patients who enter this study are randomized to one of the three regimens and followed for 24 weeks.
Trial: Randomized 3 arm (1:1:1) parallel design comparative effectiveness trial Stratification: Systemic corticosteroid/immunosuppressive therapy vs. none Treatments: 1) difluprednate 0.05% 2) combination therapy of prednisolone acetate 1% with nepafenac 0.1% 3) combination therapy of difluprednate 0.05% with nepafenac 0.1% Masking: Unmasked treatment administration; masked outcome assessment (evaluation of OCT and visual acuity) Follow-up: 2, 4, 6, 8, and 24 weeks Treatment protocol: Patients will be randomized at enrollment to either: * difluprednate 0.05% 4 drops per day * prednisolone acetate 1% 4 drops per day and nepafenac 0.1% 3 drops per day * difluprednate 0.05% 4 drops per day and nepafenac 0.1% 3 drops per day If macular edema has not resolved at Week 4, continue study treatment at the same dose until Week 6. If macular edema has resolved at Week 4, reduce study treatment as follows: * difluprednate 0.05% 1 drop per day until Week 6, then stop * prednisolone acetate 1% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 6, then stop * difluprednate 0.05% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 6, then stop If macular edema does not resolve at Week 4 but has resolved at Week 6, reduce study treatment at Week 6 as follows: * difluprednate 0.05% 1 drop per day until Week 8, then stop * prednisolone acetate 1% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 8, then stop * difluprednate 0.05% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 8, then stop If macular edema resolves at Week 4 but reoccurs at Week 6, treat per best medical judgement. After Week 8, there are no restrictions on the treatments patients may receive, and medications can be tapered further, discontinued, or changed at the discretion of the treating physician and patient preference. If a patient with previously resolved macular edema has a recurrence, the physician may treat according to best medical judgement.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
9
Difluprednate 0.05% - corticosteroid eyedrop
Nepafenac 0.1% - NSAID eyedrop
prednisolone acetate 1% - corticosteroid eyedrop
Aravind Eye Hospital
Coimbatore, Tamil Nadu, India
Aravind Eye Hospital
Madurai, Tamil Nadu, India
Aravind Eye Hospital
Pondicherry, Tamil Nadu, India
Central subfield thickness
Central subfield thickness measured by spectral domain optical coherence tomography adjusting for baseline thickness
Time frame: 4 weeks
Resolution
proportion of patients with resolution of macular edema
Time frame: 4 weeks
Improvement
proportion of patients with improvement in macular edema defined as 20% or greater reduction in central subfield thickness by OCT or resolution of edema
Time frame: 4 weeks
recurrence
proportion of patients with recurrence of macular edema defined as greater than 20% increase in central subfield thickness to a value \>320 microns by OCT or presence of cysts in an eye that previously had resolution of macular edema
Time frame: 4 weeks
Intraocular pressure (IOP) increase
number of patients with intraocular pressure increase at least 10mmHg over baseline
Time frame: 4 weeks
High IOP
Number of patients experiencing high intraocular pressure (\> 24 mmHg)
Time frame: 4 weeks
Visual acuity
best-corrected visual acuity (ETDRS protocol)
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.